Drugs / TTI-0102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04262895 | Oct 2021 | brain injury, post-traumatic stress disorder | VA Office of Research and Development | Withdrawn | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT06644534 | May 2025 → Apr 2026 overdue | MELAS syndrome | Thiogenesis Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05212662 | Sep 2024 | COVID-19, acute respiratory distress syndrome | Thiogenesis Therapeutics, Inc. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Thiogenesis Therapeutics, Inc. | Regulatory Receives FDA Rare Pediatric Disease Designation for Leigh Syndrome thiogenesis.com ↗ |
| 2026-01-23 | Thiogenesis Therapeutics, Inc. | Results Thiogenesis Presents Interim Phase 2 MELAS Data at Mitocon 2026 thiogenesis.com ↗
Results presented at Mitocon demonstrated that weight-based dosing is critical to achieving optimal exposure and tolerability, consistent with long-standing clinical experience using cysteamine in concentrations comparable to approved formulations (Cystagon® or Procysbi®) in cystinosis. |
| 2025-11-04 | Thiogenesis Therapeutics, Inc. | Results Thiogenesis Reports Interim Analysis Phase 2 MELAS Clinical Trial thiogenesis.com ↗
TTI-0102 has been well tolerated within the group, consistent with previous Phase 1 clinical trial results in healthy adults as announced in May 2022. |
| 2025-06-25 | Thiogenesis Therapeutics, Inc. | Regulatory Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH thiogenesis.com ↗ |
| 2025-01-27 | Thiogenesis Therapeutics, Inc. | Regulatory Thiogenesis Receives Final CTA Clearance for Phase 2 MELAS thiogenesis.com ↗
today announced that the European Medicines Agency (“EMA”) has accepted its Clinical Trial Application (“CTA”) Part II – National and Patient Level Documentation, for Thiogenesis’ lead compound TTI-0102. |
| 2022-05-18 | Thiogenesis Therapeutics, Inc. | Results Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102 thiogenesis.com ↗
The pharmacokinetic (PK) profile suggests the potential for once-a-day dosing at target therapeutic levels compared to four times a day dosing with Cystagon®. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Thiogenesis Therapeutics, Inc. | Receives FDA Rare Pediatric Disease Designation for Leigh Syndrome thiogenesis.com ↗ |
| 2026-01-23 | Thiogenesis Therapeutics, Inc. | Thiogenesis Presents Interim Phase 2 MELAS Data at Mitocon 2026 thiogenesis.com ↗ |
| 2025-11-04 | Thiogenesis Therapeutics, Inc. | Thiogenesis Reports Interim Analysis Phase 2 MELAS Clinical Trial thiogenesis.com ↗ |
| 2025-06-25 | Thiogenesis Therapeutics, Inc. | Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH thiogenesis.com ↗ |
| 2025-01-27 | Thiogenesis Therapeutics, Inc. | Thiogenesis Receives Final CTA Clearance for Phase 2 MELAS thiogenesis.com ↗ |
| 2022-05-18 | Thiogenesis Therapeutics, Inc. | Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102 thiogenesis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTI-0102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06644534 ↗ |
| Known as | cysteamine-pantetheine disulfide | “The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide).” NCT05212662 ↗ |
| Route | Oral | “administered orally” NCT05212662 ↗ |